1 / 16

Roxana Mehran, on behalf of the ACUITY investigators

Long-term Outcomes of Patients with ACS and Chronic Renal Insufficiency Undergoing PCI and being treated with Bivalirudin vs UFH/Enoxaparin plus a GP IIb/IIIa Inhibitor: Results from the Randomized ACUITY Trial. Roxana Mehran, on behalf of the ACUITY investigators. Disclosures. Medical

chadwick-branch
Télécharger la présentation

Roxana Mehran, on behalf of the ACUITY investigators

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Long-term Outcomes of Patients with ACS and Chronic Renal Insufficiency Undergoing PCI and being treated with Bivalirudin vs UFH/Enoxaparin plus a GP IIb/IIIa Inhibitor: Results from the Randomized ACUITY Trial Roxana Mehran, on behalf of the ACUITY investigators

  2. Disclosures

  3. Medical management UFH or Enoxaparin + GP IIb/IIIa PCI Bivalirudin + GP IIb/IIIa Angiography within 72h R* Bivalirudin Alone CABG ACUITY Study Design Moderate-high risk unstable angina or NSTEMI undergoing an invasive strategy (N = 13,819) Moderate- high risk ACS Aspirin in all Clopidogrel dosing and timing per local practice *Stratified by pre-angiography thienopyridine use or administration ACUITY Design. Stone GW et al. AHJ 2004;148:764–75

  4. Study Medications • Anti-thrombin agents (started pre-angiography) 1 Target aPTT 50-75 seconds 2 If last enoxaparin dose ≥8h - <16h before PCI; 3 If maintenance dose discontinued or ≥16h from last dose 4 Discontinued at end of PCI with option to continue at 0.25mg/kg for 4-12h if GPIIb/IIIa inhibitor not used ACUITY Design. Stone GW et al. AHJ 2004;148:764–75

  5. Primary Endpoints • Net Clinical Outcomes • Death, MI, unplanned revascularization for ischemia or non-CABG major bleeding • Composite Ischemia • Death, MI or unplanned revascularization for ischemia • Major Bleeding (Non-CABG) • Intracranial, intraocular, or retroperitoneal bleeding • Access site bleed requiring intervention/surgery • Hematoma ≥5 cm • Hgb ≥4g/dL w/o overt source • Hgb ≥3g/dL with an overt source • Reoperation for bleeding • Any blood transfusion ACUITY Design. Stone GW et al. AHJ 2004;148:764–75

  6. Background and Objectives of the Current Analysis • Background • Patients with ACS and chronic renal insufficiency have increased ischemic and bleeding complications after PCI • Objectives • Evaluate the impact of renal insufficiency and antithrombin strategy on the outcomes in patients presenting with ACS and undergoing PCI

  7. CrCl ≥60 mL/min N=5994 CrCl <60 mL/min N=1352 Management Strategy (N=13,819) CABG (n=1,539) 32.5% Medical Rx (n=4,491) 11.1% 56.4% PCI (n=7,789)

  8. Baseline Characteristics by Renal Function in PCI Patients

  9. Baseline Characteristics by Renal Function in PCI Patients

  10. 30-Day Outcomes by Renal Function in PCI Patients P<0.0001 P<0.0001 P<0.0001 30 Day Events (%)

  11. P=0.27 P=0.85 P=0.02 30 day Outcomes in Renally Impaired PCI Patients UFH/Enox + GP IIb/IIIa vs. Bivalirudin + GP IIb/IIIa vs. Bivalirudin Alone 30 Day Events (%)

  12. 30-Day Major Bleeding (non-CABG) – Renally Impaired PCI pts *P value for bivalirudin alone vs. heparin + IIb/IIIa inhibitor

  13. 1-Year Outcomes by Renal Function in PCI Patients P<0.0001 1 Year Events (%) P<0.0001

  14. 1-Year Outcomes in Renally Impaired PCI Patients by Treatment Group Hazard Ratio ±95% CI HR (95% CI) Bivalirudin Better UFH/Enox+ IIb/IIIa Better

  15. Study Limitations • Subgroup analysis, results should be considered hypothesis generating • Treatment was open label and not randomized based upon renal function

  16. Conclusions • In patients with ACS who undergo invasive management, the presence of renal insufficiency is associated with higher rates of composite ischemia and mortality at 1 year • Bivalirudin monotherapy improved early clinical outcomes compared to UFH/Enox + GP IIb/IIIa inhibitors by reducing 30-day major bleeding, and resulted in similar rates of one year composite ischemia and mortality

More Related